Renalytix Plc
RENX.L · LSE
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.23 | -0.07 |
| FCF Yield | -184.85% | -200.06% | -27.83% | -53.43% |
| EV / EBITDA | -0.68 | -0.66 | -2.51 | -1.10 |
| Quality | ||||
| ROIC | -1,238.11% | -4,348.24% | -145.43% | -99.53% |
| Gross Margin | 40.00% | 6.82% | 20.60% | 30.91% |
| Cash Conversion Ratio | 0.82 | 0.90 | 0.71 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.11% | -8.32% | 31.66% | – |
| Free Cash Flow Growth | 40.56% | 7.83% | 29.64% | -76.83% |
| Safety | ||||
| Net Debt / EBITDA | -0.22 | -0.14 | 0.30 | 0.55 |
| Interest Coverage | -34.40 | 0.00 | 0.00 | -26,591.50 |
| Efficiency | ||||
| Inventory Turnover | 9.00 | 0.00 | 3.76 | 1.77 |
| Cash Conversion Cycle | -413.67 | -331.15 | -216.39 | -111.11 |